Literature DB >> 2570958

Comparison of propofol and midazolam for sedation in critically ill patients.

A R Aitkenhead1, M L Pepperman, S M Willatts, P D Coates, G R Park, A R Bodenham, C H Collins, M B Smith, I M Ledingham, P G Wallace.   

Abstract

101 critically ill patients admitted to five intensive-care units were allocated randomly to receive a continuous intravenous infusion of either propofol or midazolam for sedation for up to 24 h. In addition, morphine was given to provide analgesia. The mean duration of infusion was 20.2 h (range 3.0-24.5) in the propofol group and 21.3 h (4.0-47.0) in the midazolam group and infusion rates were 1.77 mg/kg/h (range 0.40-5.00) and 0.10 mg/kg/h (0.01-0.26), respectively. The infusion rates were adjusted as necessary, and the desired level of sedation was achieved easily in most patients in both groups. There were slight falls in arterial pressure, but there were no significant differences between the groups. Heart rate was lower in patients who received propofol. Some small changes occurred in biochemical and haematological variables in both groups, but they were not clinically significant. There was no indication that either drug substantially impaired adrenal steroidogenesis. When the infusion was discontinued, there was less variability in recovery of consciousness in patients who had received propofol. In a subgroup of patients, weaning from mechanical ventilation was achieved significantly faster after discontinuation of propofol than of midazolam. Propofol proved to be a satisfactory agent for sedation of these critically ill patients and compared favourably with midazolam.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570958     DOI: 10.1016/s0140-6736(89)90770-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  32 in total

Review 1.  Propofol: a sedative-hypnotic anesthetic agent for use in ambulatory procedures.

Authors:  D M Steinbacher
Journal:  Anesth Prog       Date:  2001

Review 2.  Assisted ventilation. 3. General care of the ventilated patient in the intensive care unit.

Authors:  M R Hamilton-Farrell; G C Hanson
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

3.  The effect of sedation with propofol on postoperative bronchoconstriction in patients with hyperreactive airway disease.

Authors:  C M Pedersen
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

4.  Withdrawal following sufentanil/propofol and sufentanil/midazolam. Sedation in surgical ICU patients: correlation with central nervous parameters and endogenous opioids.

Authors:  Maria Korak-Leiter; Rudolf Likar; Michael Oher; Ernst Trampitsch; Gerda Ziervogel; Joseph V Levy; Enno C Freye
Journal:  Intensive Care Med       Date:  2005-02-16       Impact factor: 17.440

Review 5.  Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil.

Authors:  R Amrein; W Hetzel
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 6.  Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.

Authors:  Derek J Roberts; Babar Haroon; Richard I Hall
Journal:  Drugs       Date:  2012-10-01       Impact factor: 9.546

7.  Propofol induces bronchodilation in a patient mechanically ventilated for status asthmaticus.

Authors:  G Conti; A Ferretti; G Tellan; M Rocco; A Lappa
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 8.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

Review 9.  The use of sedative agents in critically ill patients.

Authors:  A M Burns; M P Shelly; G R Park
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

10.  Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports.

Authors:  T J Parke; J E Stevens; A S Rice; C L Greenaway; R J Bray; P J Smith; C S Waldmann; C Verghese
Journal:  BMJ       Date:  1992-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.